Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial results for the quarter ended June 30, 2013.
Maxygen reported net loss attributable to Maxygen, Inc. of $3.2 million, or $0.12 per basic and diluted share, for the second quarter of 2013, compared to net income attributable to Maxygen, Inc. of $27.1 million, or $1.00 per basic and $0.99 per diluted share, for the same period in 2012.
Hey, check out all the research scientist jobs. Post your resume today!
